CN102068405A - Ketoprofen gel and preparation method thereof - Google Patents
Ketoprofen gel and preparation method thereof Download PDFInfo
- Publication number
- CN102068405A CN102068405A CN2010105924883A CN201010592488A CN102068405A CN 102068405 A CN102068405 A CN 102068405A CN 2010105924883 A CN2010105924883 A CN 2010105924883A CN 201010592488 A CN201010592488 A CN 201010592488A CN 102068405 A CN102068405 A CN 102068405A
- Authority
- CN
- China
- Prior art keywords
- ketoprofen
- gel
- ethanol solution
- polyethylene glycol
- propylene glycol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
发明领域field of invention
本发明是一种酮洛芬凝胶制剂及其制备方法,属于药物的技术领域。 The invention relates to a ketoprofen gel preparation and a preparation method thereof, belonging to the technical field of medicines. the
背景技术Background technique
酮洛芬是具有抗炎、解热、镇痛作用的非甾体抗炎药(NSAI),酮洛芬和右酮洛芬的局部用药物制剂在大部分科学文献中被描述为刺激物、过敏原、光毒素和光过敏原。酮洛芬与其它非甾体抗炎药相类似,在临床应用过程中有严重的不良反应,如:①胃不适、胃痛、暖气、下痢等消化系统症状,②发疹、皮疹等过敏症状,③可能出现急性肾功能不全、肝功能障碍、消化性溃疡等重大不良反应。根据酮洛芬主要用于治疗慢性风湿性关节炎、变形性关节炎、腰痛症、肩关节周围炎、颈肩腕综合征,以及用于外伤消炎、镇痛的特点,为了避免以上不良反应,本研究拟采用卡波姆为水溶性材料为基质,将酮洛芬制成凝胶剂外用,目的是提高局部药物浓度,避免胃肠道等副作用,释药可控,可随时中断用药,方便用药,患者顺应性好。由于酮洛芬的口服剂量比较大,而透皮吸收由于受到皮肤的限制,药物透过量通常很小,酮洛芬不可能通过透皮吸收来实现全身给药,因此考虑将其制成局部外用制剂。局部外用制剂包括粉末制剂、半固体制剂和液体制剂。 Ketoprofen is a non-steroidal anti-inflammatory drug (NSAI) with anti-inflammatory, antipyretic, and analgesic properties. Topical pharmaceutical formulations of ketoprofen and dexketoprofen are described in most scientific literature as irritants, Allergens, phototoxins and photoallergens. Ketoprofen is similar to other non-steroidal anti-inflammatory drugs, and has serious adverse reactions during clinical application, such as: ①digestive system symptoms such as stomach discomfort, stomach pain, heating, and diarrhea; ②allergic symptoms such as eruption and rash, ③ Major adverse reactions such as acute renal insufficiency, liver dysfunction, and peptic ulcer may occur. According to the characteristics that ketoprofen is mainly used to treat chronic rheumatoid arthritis, osteoarthritis, low back pain, periarthritis of shoulder, neck, shoulder and wrist syndrome, as well as anti-inflammatory and analgesic for trauma, in order to avoid the above adverse reactions, This study intends to use carbomer as a water-soluble material as a matrix, and make ketoprofen into a gel for external use. The purpose is to increase the local drug concentration, avoid side effects such as the gastrointestinal tract, and release the drug under control. The drug can be interrupted at any time, which is convenient. Medication, patient compliance is good. Because the oral dose of ketoprofen is relatively large, and the transdermal absorption is limited by the skin, the amount of drug penetration is usually very small. It is impossible for ketoprofen to achieve systemic administration through transdermal absorption, so it is considered to be made into topical application preparation. Formulations for topical application include powder formulations, semisolid formulations and liquid formulations. the
凝胶剂是随着现代化工业发展而产生的一种新剂型,是指药物与能形成凝胶的辅料制成均一、混悬或乳剂型的乳胶稠厚液体或半固体制剂。外用凝胶剂是指药物与适宜的辅料制成的均匀或昏眩的半固体制剂,属于单相分散系统,具有溶胀性、脱水收缩性、透过性和粘合性,既有交联结构存在又具有部分的固体性质,能够在较长的时间里与用药部位紧密粘附,能使半固体制剂在静止时保持一定形状,而在外力作用下又可以流动、变形。在局部外用制剂中,往往利用这些性质来控制药物的释放或其对皮肤的粘附性。由于亲水性凝胶手感好,易洗脱,不污染衣物,目前研究的较多。构成水性凝胶基质的高分子材料可以分为天然高分子、半合成高分子、合成高分子材料。其中合成高分子材料中的卡波姆(Carbomer)为最常用基质,以其为基质可以得到均匀稳定的体系,是较理想的一类凝胶基质材料,近年来对其在透皮吸收制剂方面的应用研究较为广泛用研究较为广泛。 Gel is a new dosage form produced with the development of modern industry. It refers to the latex thick liquid or semi-solid preparation made of medicine and gel-forming excipients in uniform, suspension or emulsion form. Gels for external use refer to uniform or dizzy semi-solid preparations made of drugs and suitable excipients, which belong to a single-phase dispersion system, have swelling properties, syneresis, permeability and adhesion, and have cross-linked structures It also has a part of solid properties, which can closely adhere to the medication site for a long time, and can keep the semi-solid preparation in a certain shape when it is still, and can flow and deform under the action of external force. In topical formulations, these properties are often exploited to control the release of the drug or its adhesion to the skin. Because the hydrophilic gel feels good, is easy to wash off, and does not pollute clothes, there are many researches at present. The polymer materials constituting the aqueous gel matrix can be divided into natural polymers, semi-synthetic polymers, and synthetic polymer materials. Wherein the carbomer (Carbomer) in the synthetic macromolecular material is the most commonly used matrix, can obtain the uniform and stable system with it as matrix, is a kind of ideal gel matrix material, in recent years to its transdermal absorption preparation aspect The applied research is more extensive and the research is more extensive. the
Carbomer系丙烯酸与丙烯基蔗糖交联的高分子聚合物,为白色、疏松、酸性、吸湿性强、微有特殊臭味的粉末,由于分子中含有大量的梭基,具有亲水性,在水中迅速溶胀,但不溶解,粘度较低。用碱中和时,在水中、醇和甘油中逐渐溶解,粘度很快增大,低浓度时形成澄明溶液,浓度大时形成半透明的凝胶。如果将酮洛芬设计成凝胶剂,则既可以避免口服所引起的胃肠刺激,又可以达到局部治疗的目的,可以大大提高患者的生活质量,必将受到患者的欢迎。 Carbomer is a high-molecular polymer cross-linked with acrylic acid and propylene-based sucrose. It is a white, loose, acidic, hygroscopic powder with a slight special odor. Because the molecule contains a large number of shuttle groups, it is hydrophilic and can be dissolved in water. Swells rapidly, but does not dissolve, and has a low viscosity. When neutralized with alkali, it gradually dissolves in water, alcohol and glycerin, and its viscosity increases rapidly. It forms a clear solution at low concentration, and forms a translucent gel at high concentration. If ketoprofen is designed as a gel, it can avoid the gastrointestinal irritation caused by oral administration, and can also achieve the purpose of local treatment, which can greatly improve the quality of life of patients, and will be welcomed by patients. the
发明内容Contents of the invention
鉴于上述现有技术存在的不足,本发明的目的是提供一种稳定性和治疗效果较好的酮洛芬凝胶及其制备方法。 In view of the deficiencies in the above-mentioned prior art, the object of the invention is to provide a ketoprofen gel with better stability and therapeutic effect and a preparation method thereof. the
本发明的目的是通过如下技术方案来实现的:将由酮洛芬与无水乙醇制成的酮洛芬乙醇溶液加入到由聚乙二醇PEG400、丙二醇与卡波姆940NF制成的凝胶基质中搅拌均匀即可获得;其中上述各原料的重量百分比为:酮洛芬0.02-0.08%:无水乙醇15-40%;聚乙二醇PEG40040-80%;丙二醇10-30%;卡波姆940NFO.5-2%。 The object of the present invention is achieved through the following technical scheme: the ketoprofen ethanol solution made of ketoprofen and dehydrated alcohol is added to the gel matrix made of polyethylene glycol PEG400, propylene glycol and carbomer 940NF It can be obtained by stirring evenly in the medium; wherein the weight percentages of the above-mentioned raw materials are: ketoprofen 0.02-0.08%: absolute ethanol 15-40%; polyethylene glycol PEG400 40-80%; propylene glycol 10-30%; carbomer 940NFO.5-2%. the
其制备方法为:称取酮洛芬0.02-0.08%加入无水乙醇15-40%溶解成酮洛芬乙醇溶液备用;取卡波姆940NFO.5-2%加入聚乙二醇PEG40040-80%及丙二醇10-30%,加热70-80℃搅拌使分散均匀,再滴加三乙醇胺5%的乙醇溶液,调整PH值在3.0-6.0之间,经搅拌均匀即可获得呈透明状的凝胶基质;将上述备用的酮洛芬乙醇溶液逐渐加入到凝胶基质中,经搅拌均匀即可制成酮洛芬凝胶。 The preparation method is as follows: take 0.02-0.08% of ketoprofen and add 15-40% of absolute ethanol to dissolve it into a ketoprofen ethanol solution for later use; take carbomer 940NFO.5-2% and add polyethylene glycol PEG400 40-80% and 10-30% propylene glycol, heat at 70-80°C and stir to disperse evenly, then add dropwise 5% ethanol solution of triethanolamine, adjust the pH value between 3.0-6.0, and get a transparent gel after stirring evenly Substrate: the above-mentioned standby ketoprofen ethanol solution is gradually added into the gel matrix, and the ketoprofen gel can be made after stirring evenly. the
本发明的优点是稳定性大大优于配剂,易贮存,不易挥发。稳定性实验结果证明酮洛芬凝胶质量较稳定,各项指标无明显变化(见附表1),凝胶剂在创面存留时间长,发挥作用时间长、透皮吸收好,因而治疗效果较好。具有抗炎、解热、镇痛的作用;用于由感冒、急性上呼吸道感染,急性咽喉炎等疾病引起的发热;轻、中度疼痛;类风湿性关节:炎及骨关节炎等风湿性疾病的治疗效果显著,产品。丰富了剂型品种,市场前景十分广阔。, The advantages of the present invention are that the stability is much better than that of formulations, and it is easy to store and not easy to volatilize. Stability test results prove that the quality of ketoprofen gel is relatively stable, and there is no obvious change in each index (seeing attached table 1). good. It has anti-inflammatory, antipyretic, and analgesic effects; it is used for fever caused by colds, acute upper respiratory infections, and acute pharyngitis; mild and moderate pain; rheumatoid arthritis: rheumatoid arthritis and osteoarthritis The treatment effect of the disease is remarkable, the product. The variety of dosage forms has been enriched, and the market prospect is very broad. ,
下面结合实施例对本发明作以说明。 The present invention is described below in conjunction with embodiment. the
具体实施方式:Detailed ways:
实施例1 Example 1
制剂配方;酮洛芬2.5g;无水乙醇947.5g;聚乙二醇PEG4003000g;丙二醇1000g;卡波姆940NF 50g;三乙醇胺5%的乙醇溶液10ml。 Preparation formula: Ketoprofen 2.5g; Dehydrated alcohol 947.5g; Polyethylene glycol PEG400 3000g; Propylene glycol 1000g; Carbomer 940NF 50g; Triethanolamine 5% ethanol solution 10ml. the
制备方法:称取酮洛芬2.5g加入无水乙醇947.5g溶解成酮洛芬乙醇溶液备用;取卡波姆940NF 50g加入聚乙二醇PEG4003000g及丙二醇1000g,加热70-80℃搅拌使分散均匀,再滴加三乙醇胺5%的乙醇溶液10ml调整pH值至4.6),经搅拌均匀即可获得呈透明状的凝胶基质;将上述备用的酮洛芬乙醇溶液逐渐加入到凝胶基质中,经搅拌均匀即可制成酮洛芬凝胶5000g,杀菌,迅速降温,冷凝,干燥,即得。 Preparation method: Weigh 2.5g of ketoprofen and add 947.5g of absolute ethanol to dissolve it into a ketoprofen ethanol solution for later use; take 50g of Carbomer 940NF, add 3000g of polyethylene glycol PEG400 and 1000g of propylene glycol, heat at 70-80°C and stir to disperse evenly , then dropwise add 10ml of triethanolamine 5% ethanol solution to adjust the pH value to 4.6), after stirring evenly, a transparent gel matrix can be obtained; After stirring evenly, 5000 g of ketoprofen gel can be made, sterilized, rapidly cooled, condensed, and dried to obtain final product. the
实施例2 Example 2
制剂配方:酮洛芬2.5g;无水乙醇947.5g;聚乙二醇PEG4003000g;丙二醇1000g;卡波姆940NF 50g;三乙醇胺5%的乙醇溶液10ml。 Preparation formula: ketoprofen 2.5g; absolute ethanol 947.5g; polyethylene glycol PEG400 3000g; propylene glycol 1000g; carbomer 940NF 50g; triethanolamine 5% ethanol solution 10ml. the
制备方法:称取酮洛芬0.25g加入无水乙醇200g溶解成酮洛芬乙醇溶液备用;取卡波姆 940NF 10g加入聚乙二醇PEG400580g及丙二醇207.5g,加热70-80℃搅拌使分散均匀,再滴加三乙醇胺5%的乙醇溶液20ml(调整pH值至4.2),经搅拌均匀即可获得呈透明状的凝胶基质;将上述备用的酮洛芬乙醇溶液逐渐加入到凝胶基质中,经搅拌均匀即可制成酮洛芬凝胶1000g,杀菌,迅速降温,冷凝,干燥,即得。 Preparation method: Weigh 0.25g of ketoprofen and add 200g of absolute ethanol to dissolve into a ketoprofen ethanol solution for later use; take 10g of Carbomer 940NF, add 580g of polyethylene glycol PEG400 and 207.5g of propylene glycol, heat at 70-80°C and stir to disperse evenly , then dropwise add 20ml of triethanolamine 5% ethanol solution (adjust the pH value to 4.2), and get a transparent gel matrix through stirring; gradually add the above-mentioned standby ketoprofen ethanol solution into the gel matrix , can be made into 1000g of ketoprofen gel after stirring evenly, sterilize, cool down rapidly, condense, and dry to get final product. the
实施例3酮洛芬凝胶剂初步稳定性试验 Embodiment 3 ketoprofen gel preliminary stability test
酸碱度测定:以最佳处方制备3批样品,各取2g于小烧杯中,加50ml蒸馏水制备均匀溶液用pHS-2C型酸度计测定pH。 pH measurement: prepare 3 batches of samples with the best prescription, take 2g each in a small beaker, add 50ml of distilled water to prepare a uniform solution, and measure the pH with a pHS-2C acidity meter. the
离心试验:以最佳处方制备3批样品,各取5g,置于10ml离心管中,离心(3000r/min)30min,观察凝胶剂外观和涂展性变化。 Centrifugal test: prepare 3 batches of samples with the best prescription, take 5g each, put them in a 10ml centrifuge tube, centrifuge (3000r/min) for 30min, observe the changes in the appearance and spreadability of the gel. the
耐热实验:以最佳处方制备3批样品,置于玻璃瓶密封后,放入(60士2)℃烘箱中,24h后取出,恢复室温,观察外观、涂展性和pH的变化,并测定含量。 Heat resistance test: Prepare 3 batches of samples with the best prescription, place them in glass bottles and seal them, put them in an oven at (60±2)°C, take them out after 24 hours, return to room temperature, observe the changes in appearance, spreadability and pH, and Determination of content. the
耐寒实验:以最佳处方制备3批样品,置于玻璃瓶密封后,放入(-15士2)℃冰箱中,24h后取出,恢复室温,观察外观、涂展性和pH的变化,并测定含量。 Cold resistance test: Prepare 3 batches of samples with the best prescription, put them in a glass bottle and seal them, put them in a refrigerator at (-15±2)°C, take them out after 24 hours, return to room temperature, observe the changes in appearance, spreadability and pH, and Determination of content. the
表1、酮洛芬凝胶离心试验、耐热、耐寒试验以及酸碱度试验结果 Table 1, ketoprofen gel centrifugation test, heat resistance, cold resistance test and pH test results
从试验结果可以看出,酮洛芬凝胶剂经离心试验后,分布均匀,无分层、沉淀现象。在(60士2)℃条件下放置24h后,含量略有升高,颜色变黄,但无分层沉淀现象,可能是由于过程中有杂质产生,具体过程有待进一步研究。在(-15士2)。C条件存放过程中,凝胶剂成冰但恢复室温一段时间后,逐渐融化,含量和颜色均无明显变化,也无分层、沉淀现象。说明酮洛芬在低温下比较稳定。因此,我们建议在贮存酮洛芬凝胶剂要低温保存,尽量避免高温环境。 As can be seen from the test results, the ketoprofen gel is evenly distributed without delamination or precipitation after the centrifugal test. After being placed at (60±2)°C for 24 hours, the content increased slightly, and the color turned yellow, but there was no layered precipitation, which may be due to impurities in the process, and the specific process needs to be further studied. At (-15 ± 2). During the storage under condition C, the gel becomes ice, but after returning to room temperature for a period of time, it gradually melts, and there is no obvious change in content and color, and there is no stratification or precipitation. It shows that ketoprofen is relatively stable at low temperature. Therefore, we recommend that the ketoprofen gel should be stored at low temperature and avoid high temperature environment as much as possible. the
实施例4镇痛作用试验 Embodiment 4 analgesic effect test
本发明酮洛芬凝胶剂可明显减少醋酸等化学致痛试剂所致的小鼠扭体次数,其镇痛作用强度与萘普生相仿,昆明种小鼠30只,♀♂a各半,体重20士2g,随机分为3组,每组10只,动物腹部去毛,暴露2cm×2cm的皮肤为给药区。空白组给予空白凝胶基质0.4g,阳性 对照组给予萘普生软膏0.4g,药物组给予本发明酮洛芬凝胶剂0.4g。给药30min后,每只小鼠腹腔注射0.3%冰醋酸0.2ml。记录注射后15min内各鼠扭体次数。与空白组相比,萘普生的抑制率为63.07,本发明酮洛芬凝胶剂组的抑制率为51.11%. The ketoprofen gel of the present invention can significantly reduce the number of mouse writhing times caused by chemical pain-inducing reagents such as acetic acid, and its analgesic effect intensity is similar to that of naproxen. There were 30 Kunming mice, half and half of ♀♂a, Body weight 20 ± 2g, were randomly divided into 3 groups, 10 animals in each group, the abdomen of the animals was depilated, and the exposed skin of 2cm×2cm was the administration area. Blank group is given blank gel matrix 0.4g, and positive control group is given Naproxen ointment 0.4g, and drug group is given ketoprofen gel of the present invention 0.4g. 30 minutes after administration, each mouse was intraperitoneally injected with 0.2 ml of 0.3% glacial acetic acid. The number of times each mouse writhed within 15 minutes after injection was recorded. Compared with the blank group, the inhibition rate of naproxen was 63.07, and the inhibition rate of the ketoprofen gel group of the present invention was 51.11%.
表2、酮洛芬凝胶剂对小鼠的镇痛作用试验结果 Table 2, the analgesic effect test result of ketoprofen gel on mice
*表示与空白组相比,p<0.05。 * indicates p<0.05 compared with the blank group. the
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010105924883A CN102068405A (en) | 2010-12-16 | 2010-12-16 | Ketoprofen gel and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010105924883A CN102068405A (en) | 2010-12-16 | 2010-12-16 | Ketoprofen gel and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN102068405A true CN102068405A (en) | 2011-05-25 |
Family
ID=44027284
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010105924883A Pending CN102068405A (en) | 2010-12-16 | 2010-12-16 | Ketoprofen gel and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102068405A (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103705437A (en) * | 2012-10-08 | 2014-04-09 | 天津金耀集团有限公司 | Ketoprofen gel |
CN103784395A (en) * | 2014-02-25 | 2014-05-14 | 王丽丽 | Sufentanil gel preparation and preparation method thereof |
CN103800283A (en) * | 2014-02-25 | 2014-05-21 | 王丽丽 | Fentanyl gel preparation and preparation method thereof |
CN109303762A (en) * | 2017-07-28 | 2019-02-05 | 韩美药品株式会社 | Semi-solid preparation containing ketoprofen and preparation method thereof |
CN113476397A (en) * | 2021-07-12 | 2021-10-08 | 海南海神同洲制药有限公司 | Metronidazole gel and preparation method thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5527832A (en) * | 1994-02-05 | 1996-06-18 | Il-Dong Pharm. Co., Ltd. | Antiinflammatory and analgesic transdermal gel |
CN1767824A (en) * | 2003-03-18 | 2006-05-03 | 德国柏林开米艾克泰尼盖塞尔查福特联合股份公司 | Photostabilized topical formulations of KETOPROFEN |
CN1827094A (en) * | 2006-04-07 | 2006-09-06 | 华中科技大学 | A kind of gel type dexketoprofen patch and preparation method thereof |
CN101269073A (en) * | 2007-03-21 | 2008-09-24 | 北京德众万全药物技术开发有限公司 | Externally used anti-inflammatory pharmaceutical composition containing piketoprofen and preparation method thereof |
-
2010
- 2010-12-16 CN CN2010105924883A patent/CN102068405A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5527832A (en) * | 1994-02-05 | 1996-06-18 | Il-Dong Pharm. Co., Ltd. | Antiinflammatory and analgesic transdermal gel |
CN1767824A (en) * | 2003-03-18 | 2006-05-03 | 德国柏林开米艾克泰尼盖塞尔查福特联合股份公司 | Photostabilized topical formulations of KETOPROFEN |
CN1827094A (en) * | 2006-04-07 | 2006-09-06 | 华中科技大学 | A kind of gel type dexketoprofen patch and preparation method thereof |
CN101269073A (en) * | 2007-03-21 | 2008-09-24 | 北京德众万全药物技术开发有限公司 | Externally used anti-inflammatory pharmaceutical composition containing piketoprofen and preparation method thereof |
Non-Patent Citations (2)
Title |
---|
《中国医院药学杂志》 20050131 尹莉芳等 《美洛昔康凝胶剂的制备》 第51页左栏"2.1 处方" 1-4 第25卷, 第1期 2 * |
《药学实践杂志》 19991231 傅若秋等 《酮洛芬凝胶的制备及体外透皮试验》 第288页"2 处方及制备" 1-4 第17卷, 第5期 2 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103705437A (en) * | 2012-10-08 | 2014-04-09 | 天津金耀集团有限公司 | Ketoprofen gel |
CN103784395A (en) * | 2014-02-25 | 2014-05-14 | 王丽丽 | Sufentanil gel preparation and preparation method thereof |
CN103800283A (en) * | 2014-02-25 | 2014-05-21 | 王丽丽 | Fentanyl gel preparation and preparation method thereof |
CN103800283B (en) * | 2014-02-25 | 2015-10-28 | 王丽丽 | A kind of fentanyl gel preparation and preparation method thereof |
CN103784395B (en) * | 2014-02-25 | 2015-10-28 | 王丽丽 | A kind of sufentanil gel preparation and preparation method thereof |
CN109303762A (en) * | 2017-07-28 | 2019-02-05 | 韩美药品株式会社 | Semi-solid preparation containing ketoprofen and preparation method thereof |
CN113476397A (en) * | 2021-07-12 | 2021-10-08 | 海南海神同洲制药有限公司 | Metronidazole gel and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103462883B (en) | Matrine diatomic alcohol plastid temperature-sensitive gel and preparation method thereof | |
CN105561289B (en) | It is a kind of for treating the pharmaceutical preparation of canker sore | |
CN102068405A (en) | Ketoprofen gel and preparation method thereof | |
CN102961479A (en) | Plastics for promoting healing of skin wound and preparation method of plastics | |
WO2022032913A1 (en) | Curcumin inclusion compound temperature-sensitive gel and preparation method therefor and use thereof | |
CN106138129A (en) | A kind of Chinese medicine compound thermosensitive hydrogel agent treating oral ulcer disease | |
CN103054793B (en) | Propranolol hydrochloride cream used for treating infantile hemangioma, and preparation method thereof | |
CN105125445A (en) | Toothpaste composition | |
CN102167714A (en) | Quick and efficient method for preparing glucosamine sulfate potassium chloride compound salt | |
CN105106180A (en) | Loxoprofen sodium coating agent and preparation method thereof | |
CN103239586A (en) | Flavored agastache turbidity-dispelling external preparation as well as preparation method and application thereof | |
CN106727369B (en) | Dequalinium chloride buccal tablet and preparation method thereof | |
CN106491875A (en) | A kind of formula of antipyretic gel ballpoint and preparation method | |
CN102949555B (en) | Medicine for treating diabetic feet | |
CN102697703B (en) | Piroxicam gel preparation and preparation method thereof | |
CN101837068B (en) | Preparation technology and application of pepper eye kernel oil spray | |
CN105769844A (en) | Arginine-containing composition and preparation | |
CN102688330B (en) | Biological Chinese medicine film and preparation method thereof | |
CN102008521B (en) | Application of Chinese trumpet creeper extract to preparation of medicament for treating and resisting cerebral ischemia | |
CN100515469C (en) | Oral Liquid for Removing Sensitive Heat | |
CN104606226A (en) | Anti-bacterial inflammation-diminishing traditional Chinese medicine suppository as well as preparation method and quality control method thereof | |
CN104188895B (en) | Thiamphenicol ointment | |
CN102614115B (en) | A kind of diclofenac sodium self-emulsifying ointment | |
Mulchenko et al. | On the issue of creating medicinal products based on the marsh cinquefoil | |
CN101194923B (en) | A drug for treating systemic lupus erythematosus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20110525 |